Ireland-based Endo International plc (NASDAQ: ENDP) announced on Friday that its subsidiary Endo Ventures Limited has signed contract with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX), an Israel-based specialty pharmaceutical company, for the development, registration, supply, commercialisation and distribution of Quoin's QRX003 on an exclusive basis in Canada.
QRX003 is Quoin's lead product for Netherton syndrome, a rare, hereditary disorder.
If QRX003 receives approval, Paladin Labs Inc., an Endo operating company, will handle all commercial activities in Canada. Presently, Paladin is expecting to introduce the product in Canada in 2025.
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership
Vicinitas Therapeutics Launches with USD 65m in Series A Financing
Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals
ReCode Therapeutics Closes Series B Extension Financing Round